Cargando…
Restricting extracellular Ca(2+) on gefitinib-resistant non-small cell lung cancer cells reverses altered epidermal growth factor-mediated Ca(2+) response, which consequently enhances gefitinib sensitivity
Non-small cell lung cancer (NSCLC), one of the leading causes of cancer-related death, has a low 5-year survival rate owing to the inevitable acquired resistance toward antitumor drugs, platinum-based chemotherapy, and targeted therapy. Epidermal growth factor (EGF)-EGF receptor (EGFR) signaling act...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7447054/ https://www.ncbi.nlm.nih.gov/pubmed/32841278 http://dx.doi.org/10.1371/journal.pone.0238155 |
_version_ | 1783574235686371328 |
---|---|
author | Kim, Mi Seong Kim, So Hui Yang, Sei Hoon Kim, Min Seuk |
author_facet | Kim, Mi Seong Kim, So Hui Yang, Sei Hoon Kim, Min Seuk |
author_sort | Kim, Mi Seong |
collection | PubMed |
description | Non-small cell lung cancer (NSCLC), one of the leading causes of cancer-related death, has a low 5-year survival rate owing to the inevitable acquired resistance toward antitumor drugs, platinum-based chemotherapy, and targeted therapy. Epidermal growth factor (EGF)-EGF receptor (EGFR) signaling activates downstream events leading to phospholipase C/inositol trisphosphate (IP(3))/Ca(2+) release from IP(3)-sensitive Ca(2+) stores to modulate cell proliferation, motility, and invasion. However, the role of EGFR-mediated Ca(2+) signaling in acquired drug resistance is not fully understood. Here, we analyzed alterations of intracellular Ca(2+) ([Ca(2+)]i) responses between gefitinib-sensitive NSCLC PC-9 cells and gefitinib-resistant NSCLC PC-9/GR cells, and we found that acute EGF treatment elicited intracellular Ca(2+) ([Ca(2+)]i) oscillations in PC-9 cells but not in PC-9/GR cells. PC-9/GR cells presented a more sustained basal [Ca(2+)]i level, lower endoplasmic reticulum Ca(2+) level, and higher spontaneous extracellular Ca(2+) ([Ca(2+)]e) influx than PC-9 cells. Notably, restricting [Ca(2+)]e in both cell types induced identical [Ca(2+)]i oscillations, dependent on phospholipase C and EGFR activation. Consequently, restricting [Ca(2+)]e in PC-9/GR cells upregulated gefitinib-mediated poly (ADP-ribose) polymerase cleavage, an increase in Bax/Bcl-2 ratio, cytotoxicity, and apoptosis. In addition, nuclear factor of activated T cell (NFAT1) induction in response to EGF was inhibited by gefitinib in PC-9 cells, whereas EGF-mediated NFAT1 induction in PC-9/GR cells was sustained regardless of gefitinib treatment. Restricting [Ca(2+)]e in PC-9/GR cells significantly reduced EGF-mediated NFAT1 induction. These findings indicate that spontaneous [Ca(2+)]e influx in NSCLC cells plays a pivotal role in developing acquired drug resistance and suggest that restricting [Ca(2+)]e may be a potential strategy for modulating drug-sensitivity. |
format | Online Article Text |
id | pubmed-7447054 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-74470542020-08-31 Restricting extracellular Ca(2+) on gefitinib-resistant non-small cell lung cancer cells reverses altered epidermal growth factor-mediated Ca(2+) response, which consequently enhances gefitinib sensitivity Kim, Mi Seong Kim, So Hui Yang, Sei Hoon Kim, Min Seuk PLoS One Research Article Non-small cell lung cancer (NSCLC), one of the leading causes of cancer-related death, has a low 5-year survival rate owing to the inevitable acquired resistance toward antitumor drugs, platinum-based chemotherapy, and targeted therapy. Epidermal growth factor (EGF)-EGF receptor (EGFR) signaling activates downstream events leading to phospholipase C/inositol trisphosphate (IP(3))/Ca(2+) release from IP(3)-sensitive Ca(2+) stores to modulate cell proliferation, motility, and invasion. However, the role of EGFR-mediated Ca(2+) signaling in acquired drug resistance is not fully understood. Here, we analyzed alterations of intracellular Ca(2+) ([Ca(2+)]i) responses between gefitinib-sensitive NSCLC PC-9 cells and gefitinib-resistant NSCLC PC-9/GR cells, and we found that acute EGF treatment elicited intracellular Ca(2+) ([Ca(2+)]i) oscillations in PC-9 cells but not in PC-9/GR cells. PC-9/GR cells presented a more sustained basal [Ca(2+)]i level, lower endoplasmic reticulum Ca(2+) level, and higher spontaneous extracellular Ca(2+) ([Ca(2+)]e) influx than PC-9 cells. Notably, restricting [Ca(2+)]e in both cell types induced identical [Ca(2+)]i oscillations, dependent on phospholipase C and EGFR activation. Consequently, restricting [Ca(2+)]e in PC-9/GR cells upregulated gefitinib-mediated poly (ADP-ribose) polymerase cleavage, an increase in Bax/Bcl-2 ratio, cytotoxicity, and apoptosis. In addition, nuclear factor of activated T cell (NFAT1) induction in response to EGF was inhibited by gefitinib in PC-9 cells, whereas EGF-mediated NFAT1 induction in PC-9/GR cells was sustained regardless of gefitinib treatment. Restricting [Ca(2+)]e in PC-9/GR cells significantly reduced EGF-mediated NFAT1 induction. These findings indicate that spontaneous [Ca(2+)]e influx in NSCLC cells plays a pivotal role in developing acquired drug resistance and suggest that restricting [Ca(2+)]e may be a potential strategy for modulating drug-sensitivity. Public Library of Science 2020-08-25 /pmc/articles/PMC7447054/ /pubmed/32841278 http://dx.doi.org/10.1371/journal.pone.0238155 Text en © 2020 Kim et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Kim, Mi Seong Kim, So Hui Yang, Sei Hoon Kim, Min Seuk Restricting extracellular Ca(2+) on gefitinib-resistant non-small cell lung cancer cells reverses altered epidermal growth factor-mediated Ca(2+) response, which consequently enhances gefitinib sensitivity |
title | Restricting extracellular Ca(2+) on gefitinib-resistant non-small cell lung cancer cells reverses altered epidermal growth factor-mediated Ca(2+) response, which consequently enhances gefitinib sensitivity |
title_full | Restricting extracellular Ca(2+) on gefitinib-resistant non-small cell lung cancer cells reverses altered epidermal growth factor-mediated Ca(2+) response, which consequently enhances gefitinib sensitivity |
title_fullStr | Restricting extracellular Ca(2+) on gefitinib-resistant non-small cell lung cancer cells reverses altered epidermal growth factor-mediated Ca(2+) response, which consequently enhances gefitinib sensitivity |
title_full_unstemmed | Restricting extracellular Ca(2+) on gefitinib-resistant non-small cell lung cancer cells reverses altered epidermal growth factor-mediated Ca(2+) response, which consequently enhances gefitinib sensitivity |
title_short | Restricting extracellular Ca(2+) on gefitinib-resistant non-small cell lung cancer cells reverses altered epidermal growth factor-mediated Ca(2+) response, which consequently enhances gefitinib sensitivity |
title_sort | restricting extracellular ca(2+) on gefitinib-resistant non-small cell lung cancer cells reverses altered epidermal growth factor-mediated ca(2+) response, which consequently enhances gefitinib sensitivity |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7447054/ https://www.ncbi.nlm.nih.gov/pubmed/32841278 http://dx.doi.org/10.1371/journal.pone.0238155 |
work_keys_str_mv | AT kimmiseong restrictingextracellularca2ongefitinibresistantnonsmallcelllungcancercellsreversesalteredepidermalgrowthfactormediatedca2responsewhichconsequentlyenhancesgefitinibsensitivity AT kimsohui restrictingextracellularca2ongefitinibresistantnonsmallcelllungcancercellsreversesalteredepidermalgrowthfactormediatedca2responsewhichconsequentlyenhancesgefitinibsensitivity AT yangseihoon restrictingextracellularca2ongefitinibresistantnonsmallcelllungcancercellsreversesalteredepidermalgrowthfactormediatedca2responsewhichconsequentlyenhancesgefitinibsensitivity AT kimminseuk restrictingextracellularca2ongefitinibresistantnonsmallcelllungcancercellsreversesalteredepidermalgrowthfactormediatedca2responsewhichconsequentlyenhancesgefitinibsensitivity |